Consumer Preferences for Biosimilar Disclosures
| % Preference among Those Assigned to Disclosure Condition | % Preference among Those Not Assigned to Disclosure Condition | |
|---|---|---|
| KESTERIN is a biosimilar. | 8.7% | 8.8% |
| KESTERIN is a biosimilar. This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic | 30.7% | 26.3% |
| KESTERIN is a biosimilar. This biosimilar is a safe and effective medication and provides the same treatment benefits as MYTROZEN, an FDA-approved original biologic | 40.6% | 39.5% |
| KESTERIN is a biosimilar. This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic. Biosimilars are made from the same types of sources as the FDA-approved original biologic | 48.6% | 47.2% |
| KESTERIN is a biosimilar. This biosimilar is a safe and effective medication and provides the same treatment benefits as MYTROZEN, an FDA-approved original biologic. This biosimilar is made from the same types of sources as MYTROZEN. | 50.0% | 51.6% |
| KESTERIN is a biosimilar. This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic. Biosimilars are made from the same types of sources as the FDA-approved original biologic. KESTERIN is given the same way and has the same strength and dosage as the FDA-approved original biologic. | 69.9% | 69.0% |
| KESTERIN is a biosimilar. This biosimilar is a safe and effective medication and provides the same treatment benefits as MYTROZEN, an FDA-approved original biologic. This biosimilar is made from the same types of sources as MYTROZEN. KESTERIN is given the same way and has the same strength and dosage as MYTROZEN. | 64.8% | 66.6% |
Abbreviation: FDA, Food and drug administration.